Research Topics
Genomes and GenesSpecies | Carolyn HoppeSummaryAffiliation: Childrens Hospital & Research Center Oakland Location: Oakland, USA URL: www.rbclab.com Summary: Dr. Hoppe is an associate hematologist-oncologist and clinical scientist at Childrens Hospital & Research Center Oakland. She has been an integral team member of the Northern California Comprehensive Sickle Cell Program for the past ten years. As the medical director of the CHRCO Hemoglobinopathy Reference Laboratory and the California State Newborn Screening for Hemoglobinopathies Follow-up Program, she has has expanded the services provided by this program to include novel methods for molecular diagnostic testing for sickling and thalassemic disorders. Together with Dr. Frans Kuypers, she codirects the Red Blood Cell Laboratory to provide a resource for clinical diagnostics and translational research. She has more recently extended her research focus on genetic modifiers of stroke in sickle cell disease to clinical investigations of statins in patients with sickle cell disease. Grants: HLA Type and Stroke in Children with Sickle Cell Anemia. 1999-2001. American Society of Hematology, Fellow Scholar Award. Genetic Predictors of Stroke in Children with Sickle Cell Anemia. 2000-2005. Doris Duke Charitable Foundation, Clinical Scientist Development Award. Arginine Therapy for Acute Chest Syndrome in Sickle Cell Disease. 2001-2005. Co-investigator, FD-R-1978-01 FDA Orphan Products Development(Styles, PI). Feasibility Study to Investigate the Creation and Use of a Referral Laboratory to Assist State Newborn Hemoglobinopathy Screening Programs. 2003-2005. HRSA/National Newborn Screening and Genetics Resource Center. Genetic Determinants of Stroke Risk in Adults with Sickle Cell Anemia. 2005-2008. NHLBI Research Training Supplement to the Comprehensive Sickle Cell Centers, PA-01-079. NHLBI CSCC Collaborative Genotype-Phenotype Database and Sample Repository. 2006-2008. U54 HL70583 (Hoppe, PI). Analysis of Rh Blood Group Genes to Improve Transfusion Therapy in Sickle Cell Disease. 2007-2010. NHLBI 1R01 HL091030 (Reid, PI). Indo-US collaborative project on Maternal and Child Health and Human Development Research: Pilot study of Newborn Screening for Haemoglobinopathies in South Gujarat, India. 2008-2010. 1R03 HD57740-01 (Krishnamurti, PI). Phase I/II Trial of Simvastatin (Zocor)in Sickle Cell Disease. 2007-2011. FDA/OPD, 1R01FD-03080-01-A1 (Hoppe, PI). An Open Label, Dose Ranging Study of Prasugrel in Pediatric Patients with Sickle Cell Disease. 2011-2013. Eli Lilly and Company (Styles, PI). Publications
Research Grants
| Collaborators
|
Detail Information
Publications
Gene interactions and stroke risk in children with sickle cell anemiaCarolyn Hoppe
Department of Hematology Oncology, Children s Hospital and Research Center at Oakland, 747 52nd St, Oakland, CA 94609, USA
Blood 103:2391-6. 2004..If confirmed, these results provide a basis for population screening and targeted intervention to prevent stroke in SCA...- Evidence for HLA-related susceptibility for stroke in children with sickle cell diseaseL A Styles
Department of Hematology Oncology, Children s Hospital Oakland, Oakland, CA 94609, USA
Blood 95:3562-7. 2000..Specific HLA alleles may influence the risk of stroke in children with SCA. HLA typing may prove useful in identifying SCA patients at higher risk for stroke... - Definitions of the phenotypic manifestations of sickle cell diseaseSamir K Ballas
Department of Medicine, Cardeza Foundation for Hematologic Research, Jefferson Medical College, Thomas Jefferson University, 1015 Walnut Street, Philadelphia, PA 19107, USA
Am J Hematol 85:6-13. 2010.... - HLA type and risk of alloimmunization in sickle cell diseaseCarolyn Hoppe
Am J Hematol 84:462-4. 2009 - Newborn screening for hemoglobinopathies in CaliforniaJennifer Michlitsch
Children s Hospital and Research Center Oakland, Oakland, California 94609, USA
Pediatr Blood Cancer 52:486-90. 2009..In 1999, newborn screening for Hb H disorders was incorporated in the statewide hemoglobinopathy screening program... - Fetal haemoglobin response to hydroxycarbamide treatment and sar1a promoter polymorphisms in sickle cell anaemiaChutima Kumkhaek
Molecular and Clinical Hematology Branch, NIDDK, NIH, Bethesda, MD, USA
Br J Haematol 141:254-9. 2008..These data suggest that variation within SAR1A regulatory elements might contribute to inter-individual differences in regulation of HbF expression and patient responses to HC in SCD... - A novel RHCE*ce 48C, 733G allele with Nucleotide 941C in Exon 7 encodes an altered red blood cell e antigenKim Hue-Roye
Laboratory of Immunochemistry, New York Blood Center, New York, New York 10065, USA
Transfusion 51:32-5. 2011..We also screened blood samples from African Americans to determine the frequency of the novel allele... - Confirmation of an association between the TNF(-308) promoter polymorphism and stroke risk in children with sickle cell anemiaCarolyn Hoppe
Department of Hematology Oncology, Children s Hospital and Research Center Oakland, Oakland, CA 94609, USA
Stroke 38:2241-6. 2007..The aim of this replication study was to confirm our previous findings of associations between the TNF(-308) G/A, IL4R 503 S/P, and ADRB2 27 Q/E polymorphisms and large vessel stroke risk... - Effect of chronic red cell transfusion therapy on vasculopathies and silent infarcts in patients with sickle cell diseaseElsie Gyang
Department of Pediatrics, Stanford University School of Medicine, Palo Alto, California, USA
Am J Hematol 86:104-6. 2011..We conclude that adherence to CTX does not necessarily prevent SI or halt cerebral vasculopathy progression, especially in those with a history of overt stroke... - Bioinformatics: computers or clinicians for complex disease risk assessment?Carolyn Hoppe
Eur J Hum Genet 13:893-4. 2005 - Defining stroke risk in children with sickle cell anaemiaCarolyn Hoppe
Department of Hematology Oncology, Children s Hospital and Research Center at Oakland, Oakland, CA 94609, USA
Br J Haematol 128:751-66. 2005.... - A pilot study of the short-term use of simvastatin in sickle cell disease: effects on markers of vascular dysfunctionCarolyn Hoppe
Department of Haematology Oncology, Children s Hospital and Research Center Oakland, 747 52nd Street, Oakland, CA 94609, USA
Br J Haematol 153:655-63. 2011..Simvastatin was well-tolerated and safe. Our preliminary findings showing a dose-related effect of simvastatin on levels of NOx, CRP and IL-6 suggest a potential therapeutic role for simvastatin in SCD... - Distinct HLA associations by stroke subtype in children with sickle cell anemiaCarolyn Hoppe
Department of Hematology Oncology, Children s Hospital Oakland, CA 94609, USA
Blood 101:2865-9. 2003..If these results are confirmed in a larger study, HLA type may serve as a useful marker for the early identification of SCA patients at high risk for stroke... - A novel multilocus genotyping assay to identify genetic predictors of stroke in sickle cell anaemiaC Hoppe
Department of Hematology Oncology, Children s Hospital Oakland, Oakland, CA 94609, USA
Br J Haematol 114:718-20. 2001..These preliminary results on a small group of patients suggest that a multilocus genotyping assay may be valuable in identifying genes that increase the risk of stroke in SCA... - Use of hydroxyurea in children ages 2 to 5 years with sickle cell diseaseC Hoppe
Department of Hematology Oncology, Children s Hospital Oakland, California 94609, USA
J Pediatr Hematol Oncol 22:330-4. 2000..No unexpected toxicity occurred, and growth and development were unaffected. This pilot study suggests that hydroxyurea is safe and effective in young children with sickle cell disease... - Newborn screening for non-sickling hemoglobinopathiesCAROLYN C HOPPE
Children s Hospital and Research Center Oakland, Oakland, CA 94609, USA
Hematology Am Soc Hematol Educ Program . 2009..This review will consider the increasing prevalence of once uncommon hemoglobinopathies in the US, highlighting the rationale for expanding newborn screening beyond sickle cell disorders... - Application of flow cytometry-based genotyping for rapid detection of hemoglobin variantsS Aslanian
Hemoglobinopathy Reference Laboratory, Children s Hospital Oakland Research Institute, Oakland, CA 94609, USA
Int J Lab Hematol 29:284-91. 2007..This pilot study demonstrates the potential application of the Luminex LabMAP genotyping platform to newborn screening for definitive hemoglobinopathy testing... - Novel therapies targeting the endothelium in sickle cell diseaseCAROLYN C HOPPE
Department of Hematology Oncology, Children s Hospital and Research Center Oakland, Oakland, California 94609, USA
Hemoglobin 35:530-46. 2011..This review will discuss novel drugs, specifically targeted at the endothelium, that are currently under investigation in sickle cell disease... - Newborn screening for hemoglobin disordersCAROLYN C HOPPE
Department of Hematology Oncology, Children s Hospital and Research Center Oakland, Oakland, California 94609, USA
Hemoglobin 35:556-64. 2011.... - Prevalence of HFE mutations in California newbornsCarolyn Hoppe
Department of Hematology Oncology, Children s Hospital and Research Center at Oakland, Oakland, California 94609, USA
Pediatr Hematol Oncol 23:507-16. 2006..4/1000. As additional genetic and environmental risk factors for HHC are identified, neonatal screening may become an acceptable strategy to follow susceptible individuals and prevent clinical disease... - Pediatric thrombosisCarolyn Hoppe
Children s Hospital and Research Center at Oakland, 747 52nd Street, Oakland, CA 94609, USA
Pediatr Clin North Am 49:1257-83. 2002..Prospective and multicenter studies are still needed to clarify the contribution of specific prothrombotic disorders to childhood TE so that evidence-based treatment recommendations can be made...
Research Grants
- PHASE I/II STUDY OF SIMVASTATIN (ZOCOR) THERAPY IN SICKLE CELL DISEASECarolyn Hoppe; Fiscal Year: 2007..To determine the effect of oral simvastatin (Zocor) on vascular physiology in SCD, as measured by peripheral blood markers of endothelial injury. 2. To assess the safety and tolerability of oral simvastatin in patients with SCD. ..